About
- About Avecho
- Board & Leadership
TPM^® Technology
Portfolio
Invest
- Investor Centre
- Media Centre
Contact

Hit enter to search or ESC to close

Phosphagenics Initiates Oxycodone Patch Dosing in Phase 2 Clinical Trial

April 17, 2015

click here to read more

Post navigation

Phosphagenics Appoints Three New Directors

Appendix 3X Notices – Three New Directors

Related Posts

New Product License and Supply Agreement for US recreational cannabis market

February 2, 2022February 2, 2022

CBD soft-gel product design complete

May 21, 2021May 21, 2021

Appointment of Non-Executive Director

May 19, 2016

Recent Posts

Podcast: Money News with Scott Haywood
November 27, 2023
Placement to Advance Phase III Clinical Trial
August 28, 2023
Avecho reaches two-year stability milestone for its CBD softgel capsule
June 22, 2023

Categories

Analyst Coverage
Company Announcement
Company Report
Media Coverage
Newsletter
Press Release
Uncategorised

About us

We see a future where more patients can get even more from their treatments through innovative delivery technologies.

Stay Posted

Stay informed about our latest news and developments.

Leave this field empty if you're human:

About Avecho

TPM^® Technology

Portfolio

Investor Centre
- Investor Centre
- Media Centre

© Copyright 2019 Avecho Biotechnology Ltd.